UNITY Biotechnology Inc
NASDAQ:UBX
UNITY Biotechnology Inc
NASDAQ:UBX
Price:
0.16
USD
-20.04%
Market Closed
Market Cap:
$960k
Relative Value
There is not enough data to reliably calculate the relative value of UBX.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
UBX
Relative Value
Base Case
Not Available
Multiples Across Competitors
UBX Competitors Multiples
UNITY Biotechnology Inc Competitors
UNITY Biotechnology Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
UNITY Biotechnology Inc
NASDAQ:UBX
|
960k USD | 0 | -0 | 0.5 | 0.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.6B USD | 6.8 | 173.5 | 16.7 | 23.8 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
208.4B USD | 5.7 | 27 | 15.4 | 15.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.3B USD | 6.3 | 21.8 | 14.8 | 14.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.9B USD | 10.5 | 31.8 | 24.4 | 25.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.7 | 18.3 | 13.7 | 15.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.9B AUD | 3.2 | 16.7 | 11.4 | 14.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.9B EUR | 13.1 | 30.9 | 52.4 | 53.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
